Compare CVE & ALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | ALC |
|---|---|---|
| Founded | 2009 | 1945 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Ophthalmic Goods |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 38.7B |
| IPO Year | N/A | N/A |
| Metric | CVE | ALC |
|---|---|---|
| Price | $17.03 | $79.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $24.00 | ★ $88.71 |
| AVG Volume (30 Days) | ★ 10.8M | 1.7M |
| Earning Date | 10-31-2025 | 11-11-2025 |
| Dividend Yield | ★ 3.33% | 0.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.23 | ★ 2.10 |
| Revenue | ★ $37,063,946,178.00 | $10,185,000,000.00 |
| Revenue This Year | N/A | $5.79 |
| Revenue Next Year | N/A | $7.36 |
| P/E Ratio | ★ $13.67 | $36.89 |
| Revenue Growth | N/A | ★ 4.34 |
| 52 Week Low | $10.23 | $71.55 |
| 52 Week High | $18.75 | $99.20 |
| Indicator | CVE | ALC |
|---|---|---|
| Relative Strength Index (RSI) | 41.68 | 54.94 |
| Support Level | $16.81 | $78.29 |
| Resistance Level | $18.06 | $79.78 |
| Average True Range (ATR) | 0.44 | 1.10 |
| MACD | -0.14 | -0.09 |
| Stochastic Oscillator | 11.90 | 32.86 |
Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.